Real-time · AI · Cross-signal
Discover the power of real-time signals plus AI
Every contract, funding round, exec hire, and M&A move on NewAmsterdam Pharma Company N.V — with verified, ICP-scored contact reveals (email + mobile) on demand.
Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.
NewAmsterdam Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants
Dec 13, 2024•over 1 year ago
Contract Type
partnership
BiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma
Description
NewAmsterdam Pharma Company N.V. announced the closing of an underwritten public offering of ordinary shares and pre-funded warrants. The net proceeds to the company from the offering were approximately $452.6 million after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months